The Human Papillomavirus (HPV) vaccine is a preventive vaccine that helps protect against certain HPV infections linked to cervical cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, some throat cancers, and genital warts. It works by stimulating the immune system to develop protection before exposure to the virus and does not treat existing HPV infections or HPV-related diseases. It is a prescription vaccine administered by a healthcare professional.

Therapeutic Class: Preventive vaccine against Human Papillomavirus (HPV)-related diseases.

Pharmacological Class: Recombinant virus-like particle (VLP) vaccine.

Drug Family: Human papillomavirus vaccines.

ATC Classification: J07BM01 (Papillomavirus vaccines).

Approved:

• Prevention of persistent HPV infection.

• Prevention of cervical, vulvar, vaginal, anal, penile, and certain oropharyngeal cancers caused by vaccine-covered HPV types.

• Prevention of precancerous lesions associated with HPV.

• Prevention of genital warts caused by specific HPV types.

Commonly used for:

• Routine vaccination of adolescents before HPV exposure.

• Catch-up vaccination in eligible adolescents and adults.

Off-label use (only under medical guidance):

• No routine off-label therapeutic use. The vaccine is preventive and does not treat existing HPV infections or cervical abnormalities.

• Intramuscular injection: 0.5 mL suspension in a prefilled syringe or single-dose vial.

• Available as bivalent, quadrivalent, and 9-valent formulations depending on the brand.

The HPV vaccine contains non-infectious virus-like particles that resemble the outer surface of HPV but do not contain viral DNA. These particles stimulate the immune system to produce antibodies that help prevent future HPV infection if the vaccinated person is exposed to the virus later. Different vaccine formulations protect against different HPV types, including those most commonly associated with cervical cancer and genital warts.

Routine schedule:

• 9–14 years: Usually a 2-dose schedule, with doses given at least 5–6 months apart.

• 15 years and older: Usually a 3-dose schedule at 0, 1–2 months, and 6 months.

• Immunocompromised individuals generally require a 3-dose schedule regardless of age.

Route: Intramuscular injection, usually into the upper arm (deltoid muscle).

Missed dose: Receive the missed dose as soon as possible. The vaccination series usually does not need to be restarted.

Overdose: A serious overdose is unlikely. Seek medical advice if an excessive dose is accidentally administered.

Common:

• Pain, redness, or swelling at the injection site.

• Mild fever.

• Headache.

• Fatigue.

• Muscle aches.

Serious:

• Severe allergic reactions (rare).

• Fainting after vaccination, particularly in adolescents.

Emergency symptoms: Seek immediate medical attention if you develop:

• Difficulty breathing.

• Swelling of the face or throat.

• Severe rash.

• Persistent dizziness or loss of consciousness.

Recovery advice: Remain seated or lying down for about 15 minutes after vaccination, especially if you have a history of fainting.

Pregnancy: Vaccination is usually postponed during pregnancy unless advised otherwise by a healthcare provider.

Breastfeeding: Can generally be given during breastfeeding when appropriate.

Liver disease: No routine dose adjustment is required.

Kidney disease: No routine dose adjustment is required.

Elderly: Vaccination decisions should be based on age eligibility and individual risk.

Children: The vaccine is most effective when given before HPV exposure. Routine vaccination is recommended during early adolescence according to applicable vaccination schedules.

• Immunosuppressive medicines may reduce the immune response to the vaccine.

• The HPV vaccine can generally be administered alongside other routine vaccines using different injection sites.

• Inform your healthcare provider about all medicines and vaccines you are receiving before vaccination.

• Observe for about 15 minutes after vaccination for fainting or allergic reactions.

• Completion of the full vaccination schedule for optimal protection.

• Routine cervical cancer screening should continue according to recommended guidelines, even after vaccination.

• Bivalent HPV vaccine.

• Quadrivalent HPV vaccine.

• 9-valent HPV vaccine.

The HPV vaccine is generally administered as a standalone preventive vaccine. It may be given during the same healthcare visit as other routine vaccines using separate injection sites when appropriate.

1. https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9

2. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer

3. https://iapindia.org/immunization 

4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11111833/

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.